Ifosfamide-related acute encephalopathy: Clinical and radiological aspects

Merimsky, Ofer; Inbar, Moshe; Reider‐Groswasser, Irith; Scharf, M; Chaitchik, Samario

doi:10.1016/0277-5379(91)90330-g

Cited by 10 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…19 Morphological studies by brain CT scan show no correlation between the severity of encephalopathy and the size of the ventricles. 16,20,21 According to various studies, the EEG shows only diffuse abnormalities of non-specific cortical pain, suggesting a toxictype encephalopathy. 5,13,14 There is a relationship between EEG abnormalities and the degree of severity of clinical neurological toxicity.…”

Section: Discussionmentioning

confidence: 99%

Ifosfamide-induced encephalopathy: about 15 cases and review of the literature

Filali¹,

Elmouhtadi²,

Daoudi³

et al. 2020

JCPCR

View full text Add to dashboard Cite

During Ifosfamide treatment, encephalopathy may occur in about 3% of cases. Additional investigations, such as biology or imaging, are usually normal. Encephalopathy is generally reversible without medium-or long-term sequelae but rare cases of death are described. It is recommended, as soon as Ifosfamide encephalopathy is suspected, to suspend its administration, to correct any hydroelectrolytic disorder, and to inject methylene blue at a dose of 50 mg every 4 hours until the symptoms regress. Reintroduction of Ifosfamide in subsequent courses of treatment should be discussed on a case-by-case basis, under prophylactic treatment with methylene blue at a dose of 50 mg every 6 hours. The mechanism of this complication is not fully elucidated. It is important to continue pharmacological studies in order to determine precisely the toxic metabolite(s) responsible and thus to look for an effective protector.

show abstract

Section: Discussionmentioning

confidence: 99%

Ifosfamide-induced encephalopathy: about 15 cases and review of the literature

Filali¹,

Elmouhtadi²,

Daoudi³

et al. 2020

JCPCR

View full text Add to dashboard Cite

show abstract

“…Ifosfamid-encephalopathy [2] is observed in 10%-50% of the patients. It develops 12-16 hours after treatment initiation.…”

Section: Brain Dysfunction and Lesionsmentioning

confidence: 97%

Neurological complications of medical anti-cancer therapies

Hildebrand

2008

Oncol Rev

View full text Add to dashboard Cite

This review describes the features of central and peripheral neurological disorders caused by anti-cancer chemotherapy and supportive medications, such as antiepileptic drugs, glucocorticosteroids and opioids, frequently used in cancer patients. Diffuse encephalopathy with or without epileptic seizures, cerebellar disorders and aseptic meningitis may occur after systemic administration of conventional drug doses, but their incidence is much higher when either high-dose chemotherapy, or intrathecal or intracarotid administration is used. Spinal cord and/or spinal root lesions have been reported after intrathecal administration of methotrexate or cytosinearabinoside. Anti-cancer chemotherapy is the leading cause of peripheral neuropathy in cancer patients. The main culprits are vinca alkaloids, platinum derivatives and taxanes. Anti-cancer chemotherapy has no significant toxic effect on muscle tissue, but heavy administration of glucocorticosteroids is a common cause of disabling, predominantly pelvic, muscle atrophy.

show abstract

Neurologic Complications of Therapy

Bradley¹,

Robins²

Oncology

View full text Add to dashboard Cite

Ifosfamide-related acute encephalopathy: Clinical and radiological aspects

Cited by 10 publications

References 7 publications

Ifosfamide-induced encephalopathy: about 15 cases and review of the literature

Ifosfamide-induced encephalopathy: about 15 cases and review of the literature

Neurological complications of medical anti-cancer therapies

Neurologic Complications of Therapy

Contact Info

Product

Resources

About